Background The purpose of this study was to evaluate the cost-effectiveness of antidepressants vs active monitoring (AM) for patients with mild-moderate major depressive disorder. Methods This was a 12-month observational prospective controlled trial. Adult patients with a new episode of major depression were invited to participate and assigned to AM or antidepressants according to General Practitioners' clinical judgment and experience. Patients were evaluated at baseline, and 6 and 12-month follow-up. Quality-adjusted life years (QALYs) gained were estimated and used to calculate incremental cost-utility ratios (ICUR) from the healthcare and government perspective. To minimize the bias resulting from non-randomization, a propensity score-based method was used. Results At 6 and 12-month follow-up, ICUR was 2549 €/QALY and 6,142 €/QALY, respectively, in favor of antidepressants. At 6 months, for a willingness to pay (WTP) of 25,000 €/QALY, antidepressants had a probability of 0.89 (healthcare perspective) and 0.81 (government perspective) of being more cost-effective than AM. At 12 months, this probability was 0.86 (healthcare perspective) and 0.73 (government perspective). Conclusions Incremental cost-utility ratios favor pharmacological treatment as a first-line approach for patients with mildmoderate major depressive disorder. While our results should be interpreted with caution and further real world research is needed, clinical practice guidelines should consider antidepressant therapy for mild-moderate major depressive patients as an alternative to active monitoring in PC.
Background
Active monitoring (AM) has been proposed as an adequate approach for the management of mild-to-moderate major depression [1, 2] , which is usually treated in primary care (PC) [3, 4] . Mild-to-moderate forms of major depression fulfil all DSM-IV criteria for major depression, including the presence of five out of the nine of possible symptoms for at least 2 weeks, but present with mild-moderate functional impairment. In AM, the patient and general practitioners (GP) agree to observe the development of symptoms before starting treatment with antidepressants [5] . Although variations exist across regions, AM implies close monitoring of the course of the illness by the GP, who may accompany monitoring with low-intensity psychosocial interventions such as brief cognitive behavioral therapy (CBT), counseling, or problem-solving therapy (PST) [1, 2] . The GP can also recommend the self-help programs or moderate-intensity exercise programs. If symptoms worsen, the GP could suggest initiating treatment with antidepressants or refer the patient to specialized care as part of the AM intervention.
Antidepressants are the first-line treatment options for high-risk patients with mild-to-moderate major depression [1, 2] but have been shown to have limited benefits in 1 3 patients with mild-to-moderate depressive symptoms [6] . Most clinical practice guidelines (CPG) for the treatment of major depression in PC recommend AM as the first-line treatment. Diagnostic concordance between GP and structured validated interviews is low [7, 8] and a high proportion of patients without mood disorders are treated with antidepressants and other psychotropic drugs [9] . Routine use of AM could limit the exposure of patients with minor depression or psychological distress to antidepressants. Other advantages of AM include avoiding the side-effects of drugs and their interactions as well as limiting the burden of the stigma associated with the treatment.
However, in real-life routine practice conditions, the heavy burden on physicians, their lack of training in psychotherapy, and their attitudes towards mental health could limit adherence to clinical-guideline recommendations on AM interventions [10, 11] , leading to patients receiving no treatment at all [5] . Lack of treatment could result in worsening symptoms and increasing costs associated with health service use and productivity losses.
Available evidence on the efficiency of AM in comparison with antidepressants is limited and contradictory. An economic evaluation comparing treatment with and without antidepressants in patients with minor or mildmajor depressive disorder observed no differences in costeffectiveness between the two treatment strategies [12] . Conversely, the THREAD study [13] showed that the use of antidepressants plus supportive care could be more efficient than supportive care alone, although the probability of the intervention with antidepressants being more costeffective was only 75% for a value of £30,000 per QALY and the probability of the intervention being more costeffective diminished from 12 to 26 weeks.
In this study, we evaluated the cost-effectiveness of AM in comparison with antidepressants for the treatment of mild-to-moderate major depression in PC. The study aimed to evaluate AM in an observational controlled trial.
Methods
This was a 12-month observational controlled trial conducted in 12 PC practices in Barcelona (Spain) [14] . The participating GPs (n = 53) received two 1.5-h training sessions on the diagnosis of major depression and non-pharmacological treatment (AM, sleep hygiene, counseling, frequency of follow-up visits, health education, and lowintensity psychological therapies) and pharmacological treatment for major depression. Monthly newsletters were sent to the GPs to remind them about the content of the training sessions.
Participants
Adult patients with a new episode of major depression were invited to participate (June 2013-July 2014). We excluded patients who had taken an antidepressant medication in the previous 60 days; those presenting psychotic or bipolar disorders or those who had taken antipsychotics, lithium, or antiepileptics in the previous 6 months; those with history of drug abuse or dependency; and those with cognitive impairment that prevented an assessment interview.
Interventions
Participants were assigned to AM or antidepressants according to GPs' clinical judgment and experience. AM was delivered as in real-life routine practice. The Catalan CPG recommends monitoring the patient within 15 days following diagnosis when conducting AM [2] . Over the following 10-12 weeks, the guidelines recommend six-to-eight followup visits. The GPs could consider low-intensity psychosocial therapies and structured moderate-intensity exercise programs. If the patient's condition does not improve, GPs can initiate antidepressants. Adherence to AM was controlled through patient interviews.
The patients in the medication group received the antidepressants typically prescribed in Spanish PC at doses usually recommended according to their symptoms and characteristics. The national guidelines recommend initiating treatment with SSRIs [2] . Adherence to antidepressants was assessed though medical record information (prescription filled).
Data collection and measures
Prior to the study, GPs completed a questionnaire on sociodemographic characteristics, job characteristics, training, attitude towards depression, interest in mental health, and participation in communication groups [15] . Patients were evaluated at baseline, and 6 and 12-month follow-up.
Service utilization and cost measures
Healthcare sector and government perspectives were used for the analysis. Using the Client Service Receipt Inventory [16] , we collected information on medical tests, emergency visits, hospital stays and visits to psychologists, psychiatrists, other specialists, GP, and nurse and social worker. Information on the use of psychotropic medicines and productivity losses were collected from medical records to improve accuracy.
The Catalan Government Official Bulletin was reviewed to retrieve public health service tariffs for 2015. The reference price of the generic version of drugs was extracted from the Spanish Drugs Catalogue and used to calculate the mean price per milligram of the antidepressants prescribed. Productivity losses were calculated based on the human capital approach using information on the minimum and average daily wage in Spain [17] . Table 1 shows unit costs used in the study.
Clinical outcomes
Clinical outcomes were assessed at baseline, and 6 and 12 months by an external researcher. The European Quality of Life instrument (EuroQol-5D-3L) was used to measure health-related quality of life [18, 19] . QALYs were calculated by multiplying the utility based on EQ5D by the amount of time that a patient spent in this particular health state. Transitions between health states were linearly interpolated [20] . We used the Patient Health Questionnaire 9 (PHQ-9) to assess changes in depression severity [21] [22] [23] .
The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) was used to confirm clinical diagnosis [24] . GPs were blind to the DSM-IV diagnosis and patient inclusion was based on their criteria. Sociodemographic characteristics and chronic physical conditions were assessed using checklists.
Further details on the battery of measures are provided elsewhere [14] .
Statistical analysis
A detailed description of the statistical methods is provided in the Supplementary files. The base-case analysis was an intention-to-treat analysis. To deal with missing data, we used multiple imputations by chained equations.
To minimize the bias resulting from non-randomization, a propensity score-based method-the inverse probabilityweighted and regression-adjustment method (IPWRA)-was used [25] .
Differences in costs and QALYs between groups were estimated using weighted regression models. A secondary analysis was performed in which effects were measured in terms of increased probability of remission of depressive symptoms. We ran these models in each of the imputed databases and combined resulting estimates in differences in costs and QALYs to calculate incremental cost-effectiveness ratios (ICER = mean difference in costs/mean difference in effects).
We used bootstrapping (5000 replications) to assess uncertainty, and to construct cost-effectiveness planes and cost-effectiveness acceptability curves.
Five sensitivity analyses were performed: (1) an analysis not adjusted for the propensity score; (2) an analysis including only patients that fulfilled DSM-IV criteria for MDD; (3) an analysis using the mean average salary instead of the minimum average salary for productivity losses; (4) a per protocol (PP) analysis; (5) an analysis of completers.
For the PP analysis, adherence in the AM group was defined as receiving at least three follow-up visits and one of the recommended interventions. Adherence in the antidepressants group was defined as having a medication possession ratio ≥ 0.8.
Based on the previous experience in studies with similar populations and setting [26] [27] [28] , we aimed to include 150 patients per treatment arm [14] . Figure 1 presents the study flowchart. Overall, 263 patients with a new episode of mild-moderate major depressive disorders were included in the study and received AM (118) or antidepressants (145). Some 26% of the participants were lost to follow-up and there were no statistically significant differences between study arms in attrition rate. Forty (AM) and eighty-eight (antidepressants) patients adhered to the intervention and were included in the PP analysis. Table 2 presents the characteristics of the sample. Most participants were women, with a mean age of 49 years and either primary or primary/secondary level of education. Only 30% of participants were in paid employment and only 31% had major depressive disorder according to DSM-IV criteria. Most GPs were women (85%; n = 45) with a mean age of 44.3 (SE = 1.03) (range 30-60).
Results
At baseline, patients with a panic disorder with agoraphobia or dysthymia and those with more positive perceptions about medications or a higher disability had a higher probability of receiving antidepressants (p < 0.05). After adjusting for the propensity score, no statistically significant differences existed between groups. Table 2 shows the number and type of non-pharmacological interventions applied, as reported by patients. The AM arm received a greater number of interventions, although a low number of interventions were applied. Considering specific interventions, the only differences between groups were observed in the proportion of patients receiving physical exercise recommendations and alternative therapies. There were no differences between arms in the mean number of follow-up visits.
Cost-effectiveness of antidepressants vs AM
A comparison of components of costs is provided in Supplementary Table 1 . Both at 6 and 12 months, the antidepressants arm made higher costs on pharmacological treatment. No other statistically significant differences in costs were observed. Table 3 shows the results of the cost-effectiveness analysis after 6 and 12-month follow-up for the base-case and all the sensitivity analyses.
Base-case analysis
At 6 months, there was a small non-statistically significant difference in costs between groups from both the government and healthcare perspectives. Non-statistically significant gains in QALY were observed in favor of patients prescribed antidepressants. The incremental cost-utility ratio was 2177 €/QALY gained (government perspective) and 2549 €/QALY gained (healthcare perspective) in the antidepressants treatment arm. Figure 2 shows cost-utility planes from the government and healthcare perspectives at 6-month follow-up. In the analysis using the government perspective, 53.8% of the cost-utility pairs were in the north-east quadrant (more effective and more expensive) and 40.9% in the south-east quadrant (more effective and less expensive). Similar results were found from the healthcare perspective. Figure 2 shows the cost-utility acceptability curves. For a willingness to pay (WTP) of 25,000 €/QALY gained, the probability of antidepressants being more cost-effective than AM was 80.8% from the healthcare perspective and 89.1% from the government perspective.
At 12 months, no statistically significant differences in costs or effects were observed between groups. The mean difference in QALYs was 0.03 in favor of patients in the antidepressants arm. Patients receiving antidepressants generated a mean of 269 € (government perspective) and 156 € (healthcare perspective) extra costs, resulting in an ICUR of 10,593 €/QALY and 6142 €/QALY from the government and healthcare perspectives, respectively.
Concerning cost-effectiveness planes, similar results were observed from both perspectives, with most of the costeffectiveness pairs in the north-east quadrant (76.5% from the government perspective and 77% from the health-care perspective). Antidepressants had a 72.6% and 86.1% probability of being more cost-effective than AM if WTP was 25,000 € from the government and healthcare perspectives, respectively (Fig. 2) .
Sensitivity analyses
All five sensitivity analyses showed mostly consistent results with small differences in costs and effects between groups both at 6 and 12-month follow-up. These results were in line with the findings of the main analyses. Statistically significant differences in QALYs were seen at 6 and/or 12 months in favor of antidepressants in the sensitivity analysis using generalized linear models without propensity score correction and when only those patients with major depression according to DSM-IV criteria were included.
At 6 months, differences in costs ranged from − 548.3 € to 137.6 €, while differences in QALY ranged between 0.01 and 0.03. In three scenarios (patients with a DSM-IV diagnosis of depression, PP analysis, and completers' analysis), antidepressants dominated AM. In the other analyses, the highest ICUR was 10,226 €/QALY. Cost differences at 12 months varied from − 162€ to 688 €, while effect differences were 0.03-0.08. In the PP analysis, antidepressants dominated AM. In the remaining analyses, the ICUR ranged from 690 to 27,092 €/QALY.
Fig. 1 Flow of the participants in the study

Remission of symptoms
Supplementary Table 2 shows the results of the costeffectiveness analysis in terms of remission of depressive symptoms after 6 and 12-month follow-up for the base-case and all the sensitivity analyses. No statistically significant differences between groups were observed in either difference of costs or remission of symptoms at any follow-up point or sensitivity analysis. At 6-month follow-up, the antidepressants arm generated higher costs and effects in the main analysis and most sensitivity analyses. Antidepressants dominated AM in the PP and completers' analyses. At 12 months, antidepressants generated higher costs and had a lower probability of leading to a remission of symptoms in most of the analyses.
Discussion
Although many CPG recommend AM for the treatment of mild-to-moderate major depression in primary care [1, 2] , evidence regarding its effectiveness and efficiency is scarce and contradictory [29, 30] . Results from our nonrandomized study show that incremental cost-utility ratios favor antidepressants as a first-line approach for patients with mild-moderate major depressive disorder over the active monitoring (AM) approach, in particular during the first 6-month follow-up, although neither differences in costs or benefits were statistically significant. Differences in costs and QALY may not reach statistical significance in the main analyses nor in most of the sensitivity analyses, but cost-utility acceptability curves show that antidepressants have a higher probability of being more costeffective than AM, especially from a healthcare perspective and after 6 months of treatment. Nevertheless, this difference is not sustained over time, as results at 12 months show a decline in relation to ICUR values that could be due to many factors including the natural remission of the disease [31] . As a consequence, conclusions might be difficult to draw after 1 year. Incremental cost-utility ratios for the main analyses and the sensitivity analyses at both follow-up points are below the recently published limits for Spain (20,000 €-25,000 €/ QALY) [32] and well below values in other European countries [33] . Although the aim of this study was to shed light on whether AM in mild-moderate MDD could be a feasible and cost-effective alternative to pharmacological interventions in the current PC practice, the results are inconclusive and difficult to interpret. The literature from other European countries also underlines difficulties in supporting a full AM approach for the treatment of mild-to-moderate MDD. The THREAD study [13] claimed that adding an antidepressant seemed to be more efficient, although they only followed patients up for 6 months and the probability of the intervention being cost-effective dropped from 3 to 6 months, when it was only 75% for a WTP of £30,000 per QALY. Bosmans et al. 2008 followed up 89 patients for 12 months and found no differences between patients in the antidepressants group and the non-pharmacological group. However, they pointed out that the limited sample size and drop-outs could have limited their capacity to detect differences [12] .
The sensitivity analyses showed small variations in the results. In all cases, the results favoured antidepressants, with ICUR below the willingness to pay threshold in Spain (25,000 €/QALY) in all the sensitivity analysis with the exception of the one that used the average absenteeism salary for sick leave (ICUR = 27,092 €/QALY). The antidepressants groups dominated the AM approach in the PP analysis and when patients with MDD according to DSM-IV criteria were examined. Although conclusions should be considered with caution, mainly due to limited sample size and followup duration, it seems that patients meeting diagnostic criteria for MDD and those who adhere to the interventions have a better response to the pharmacological treatment. It is increasingly recognized that the majority of patients who attend a PC practice present sub-threshold depressive symptoms, which do not meet the full diagnostic criteria for MDD, but can be very disabling with respect to everyday life functionality [1] . As a consequence, and bearing in mind the naturalistic aim of the study, these results must be interpreted carefully when choosing the best treatment approach for depressed patients in a PC setting. Sensitivity analyses of this type were not conducted in the previous studies and need to be explored in the future.
Strengths and limitations
This is the study with the largest sample size and longest follow-up period to compare the cost-effectiveness of antidepressants and AM [29, 30] . Furthermore, the naturalistic aim of the study and the participation of PCHCs from very different parts of the city and surroundings areas of Barcelona increase the external validity of the results. However, the study has a series of limitations that must be considered when interpreting its results. Although this was the study with the largest sample size evaluating this topic, it may have been underpowered to detect differences in costeffectiveness. The naturalistic nature of the study implies the use of wide inclusion criteria, non-randomized group assignment, and lack of blinding for physicians and participants, and could have introduced bias. It seems likely that GPs will allocate patients presenting more severe symptoms to the antidepressants arm, giving it more opportunities for improvement. There were no statistically significant differences in the sociodemographic or clinical characteristics between the two treatment arms with the exception of the presence of panic disorder, which was more frequent in the AM group, which is likely a spurious result. In addition, factors determining the use of pharmacological or non-pharmacological interventions are likely to be related to patient preferences, GPs' habits, and PC centre traditions (biomedical vs biopsychosocial models) and confidence in the use of antidepressants and/or brief psychological interventions. To reduce bias from the lack of randomization, propensity score techniques were used to balance groups. These techniques have previously been used in quasi-experimental studies and economic evaluations to limit the impact of non-randomization [34] [35] [36] [37] . However, it is possible that the observed differences are due to unmeasured confounders. This is a particular issue in this case, since the differences in costs and effects are small, so it would only take a small confounding effect to alter the results.
Participants reported that GPs applied very few interventions by in relation to the depressive episode. Around 50% of participants reported receiving active listening, but, among the interventions recommended by the CPG, the only differences between groups were for PST and only 15% of patients had received it in the AM group. Memory bias could partially explain these low rates of interventions reported. To guarantee naturalistic conditions in the present study, GPs received brief training on AM principles, but no strict intervention protocol was used. Furthermore, non-adherence to antidepressants and AM could also reduce its effectiveness on the antidepressants group [38, 39] . A sensitivity analysis using a PP analytical strategy was performed to determine the impact of adherence to the protocol in both the AM and antidepressants groups.
Almost 26% of participants were lost to follow-up. To minimize this, we used multiple imputation techniques and also conducted a complete case analysis.
The results of this study indicate that adherence to active monitoring is low. Future research should explore the barriers that primary care physicians encounter when trying to conduct active monitoring, taking into account also the patient perspective. The results of these studies would be useful to design strategies to enhance adherence to active monitoring recommendations, improving their effectiveness and their efficiency in the clinical practice. Furthermore, the cost-effectiveness of AM in comparison with antidepressants should be evaluated in patients with different psychiatric diagnosis. The problem of adequate diagnosis of depression in PC not only affects AM. Strategies to improve the adequacy of diagnosis and treatment of depression in PC should be developed and implemented, and their impact on the efficiency of AM should be evaluated.
Conclusions
There is not enough information available to conclude that AM in mild-moderate MDD is a feasible and cost-effective alternative to pharmacological interventions in the current PC practice. On the contrary, up to 12-month follow-up, it seems that incremental cost-utility ratios favor pharmacological treatment as a first-line approach to improve quality of life in these patients. Due to the high prevalence of the disease and the impairment generated by it, which is a great burden on the PC setting, efforts should be directed to train GP in effective and efficient interventions. In view of the results of this and previous studies, CPGs should review the recommendations for mild-moderate major depression, so that they reflect available resources in PC while more research is carried out with larger sample sizes and longer follow-up periods and in different countries and contexts.
